Streetwise Reports' Article Archives — Current Month (12)
Two Use Cases for AI in Healthcare (03/14/2025)
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology.
US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons (03/14/2025)
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.
Biotech Stock Looks Like Is Has a Great Set Up (03/12/2025)
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy.
Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients (03/12/2025)
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note.
AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial (03/11/2025)
Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches.
Biotech Advancing Pivotal Phase III Breast Cancer Trial (03/11/2025)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.
FDA OKs Trial of Cell Reservoir in Thyroid Disease (03/10/2025)
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.
With Competitor Out, New Drug Gains Edge in Chronic Cough (03/10/2025)
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report.
New Drug for Major Depressive Disorder Gets Good Surprise (03/10/2025)
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report.
Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ (03/06/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock.
Canadian Healthcare Co. Showcases Stable FQ424 (03/06/2025)
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.
Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data (03/05/2025)
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next.
More Archives
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
